BIOINVEST BREAKING NEWS – Celldex (CLDX) — This morning – CLDX announced that both Phase III registration trial of barzolvolimab (“barzo”) met their primary endpoints with high statistical significance (p<0.00001); unequivocal data and Best-In-Class profile. BUY (...more)
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.